2,177 reports of this reaction
1.4% of all DICLOFENAC POTASSIUM reports
#7 most reported adverse reaction
JOINT SWELLING is the #7 most commonly reported adverse reaction for DICLOFENAC POTASSIUM, manufactured by Assertio Therapeutics, Inc.. There are 2,177 FDA adverse event reports linking DICLOFENAC POTASSIUM to JOINT SWELLING. This represents approximately 1.4% of all 156,718 adverse event reports for this drug.
Patients taking DICLOFENAC POTASSIUM who experience joint swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
JOINT SWELLING is a less commonly reported adverse event for DICLOFENAC POTASSIUM, but still significant enough to appear in the safety profile.
In addition to joint swelling, the following adverse reactions have been reported for DICLOFENAC POTASSIUM:
The following drugs have also been linked to joint swelling in FDA adverse event reports:
JOINT SWELLING has been reported as an adverse event in 2,177 FDA reports for DICLOFENAC POTASSIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
JOINT SWELLING accounts for approximately 1.4% of all adverse event reports for DICLOFENAC POTASSIUM, making it a notable side effect.
If you experience joint swelling while taking DICLOFENAC POTASSIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.